Does angiotensin receptor-neprilysin inhibition improve clinical and echocardiographic outcomes in heart failure patients with end-stage kidney disease on maintenance dialysis?
ARNI appears beneficial and safe in heart failure patients with end-stage kidney disease on maintenance dialysis, improving LV function and reducing mortality without increasing hyperkalemia or hypotension.
This meta-analysis provided insights into the benefits of ARNI in HF patients with ESKD undergoing dialysis by improving left ventricular function, reversing left ventricular remodelling, and reducing the risk of all-cause mortality, without increasing the risk of HF hospitalizations, severe hyperkalaemia, and symptomatic hypotension.
Dũng et al. (Mon,) studied this question.